Vijay Agarwal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5856310/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. Journal of Proteomics, 2012, 75, 2745-2752.	2.4	36
2	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews, 2011, 37, 533-542.	7.7	31
3	Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: A possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 2012, 75, 1276-1283.	2.4	28
4	PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 2013, 34, 847-851.	1.8	20
5	Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. Journal of Medical Case Reports, 2008, 2, 227.	0.8	13
6	Is EGFR really a therapeutic target in head and neck cancers?. Journal of Surgical Oncology, 2019, 119, 685-686.	1.7	12
7	Clinical response to primary letrozole therapy in elderly patients with early breast cancer: Possible role for p53 as a biomarker. International Journal of Surgery, 2014, 12, 821-826.	2.7	5
8	Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 2013, 42, 1088-1092.	3.3	3
9	Urethral metastasis from non-seminomatous germ cell tumor: a case report. Journal of Medical Case Reports, 2011, 5, 12.	0.8	2
10	The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma. Pathology and Oncology Research, 2020, 26, 985-995.	1.9	0
11	Human epidermal growth factor receptor-2 expression in head and neck squamous cell carcinoma: A	0.2	0